Polypeptide of affinity GP2 and application thereof
Through the reverse-inverted GP2 affinity peptide DGPBP-2 (1-8) and modification technology, the problem of poor absorption of peptides in the intestine is solved, efficient drug absorption and resistance to enzyme degradation, and new drug development is provided Ideas.
Patent Information
- Application Number
- CN202411245001.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-11-29
AI Technical Summary
Multiple drugs such as polypeptides have poor absorption in the intestine and require frequent injections. Oral absorption requires the assistance of absorption promoters. The special structure of intestinal M cells shortens the intracellular transport distance of the drug but lacks lysosomes, which affects the integrity of drug transport.
Develop an inverse-inverted GP2 affinity peptide DGPBP-2 (1-8), which is screened and chemically synthesized through the phage display peptide library, combined with modification techniques, such as phosphorylation, coupling protein, nanocarrier coupling, etc. Prolong the half-life, increase water solubility, reduce toxic side effects, and improve the absorption efficiency of drugs in the intestines.
DGPBP-2 (1-8) can specifically affinity with GP2 receptors, resist enzyme degradation, and improve the absorption efficiency of drugs in the intestinal tract. As the basis of oral preparations or other preparations, it provides new development for the development of anti-tumor or other diseases. ideas.
Smart Images

Figure BDA0005030402930000041 
Figure BDA0005030402930000071 
Figure BDA0005030402930000081
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biomedicine, and specifically relates to a polypeptide having affinity to GP2 and application thereof. Background Art
[0002] Many drugs, such as peptides, are well soluble in water and poorly absorbed by the intestines. They require frequent injections and poor patient compliance. Oral administration is a method of administration with good compliance, and oral absorption of drugs usually requires the assistance of absorption enhancers. There is a specialized epithelial cell in the intestines - M cells (microfold cells), which have the function of taking up and transporting particles and drugs in the intestinal cavity. The surface of M cells lacks normal intestinal villi and the basement membrane is concave inward to form a "pouch structure". This special "pouch structure" shortens the intracellular transport distance of the drug, and its cytoplasm lacks lysosomes, which ensures the integrity of the drug during transport. GP2 is an endocytic receptor expressed on the surface of intestinal M cells. Screening for GP2 affinity peptides can help assist drug absorption in the intestine. Summary of the invention
[0003] The first aspect of the present invention aims to provide a polypeptide having affinity to GP2.
[0004] The second aspect of the present invention aims to provide biological materials related to the polypeptide of the first aspect of the present invention.
[0005] The third aspect of the present invention aims to provide the use of the polypeptide according to the first aspect of the present invention or the biomaterial according to the second aspect of the present invention.
[0006] The fourth aspect of the present invention aims to provide a vaccine.
[0007] The purpose of the fifth aspect of the present invention is to provide a product.
[0008] In order to achieve the above object, the technical solution adopted by the present invention is:
[0009] The first aspect of the present invention provides a polypeptide, characterized in that the polypeptide is any one of a1) to a4):
[0010] a1) the amino acid sequence is shown in any one of SEQ ID NO: 1 to SEQ ID NO: 11 and SEQ ID NO: 13;
[0011] a2) a retro-inverted form of the amino acid sequence of X1-X2-X3-X4-X5-X6-HRSTHV,
[0012] Among them, X1 does not exist or is A;
[0013] X2 does not exist or is T;
[0014] X3 does not exist or is L;
[0015] X4 does not exist or is H;
[0016] X5 does not exist or is S;
[0017] X6 does not exist or is A;
[0018] a3) a retro-inverted form of the amino acid sequence of ATLHSA-X7-X8-X9-X10-X11,
[0019] Wherein, X7 does not exist or is H;
[0020] X8 does not exist or is R;
[0021] X9 does not exist or is S;
[0022] X10 does not exist or is T;
[0023] X11 does not exist or is H;
[0024] a4) A modified form of any of the polypeptides a1) to a3).
[0025] In some embodiments of the present invention, all amino acids in a1) are L-amino acids, or at least the amino acids at both ends of the polypeptide are D-amino acids.
[0026] In some embodiments of the present invention, the amino acids of the polypeptide in a2) are shown in any one of SEQ ID NO: 16 to SEQ ID NO: 22; and all the amino acids of the peptide are D-amino acids.
[0027] In some embodiments of the present invention, the amino acids of the polypeptide in a3) are shown in any one of SEQ ID NO: 24 to SEQ ID NO: 28; and all the amino acids of the peptide are D-amino acids.
[0028] In some embodiments of the present invention, the modification sites of the modification forms described in a4) include N-terminal modification, C-terminal modification, backbone modification, side chain modification and / or amino acid modification. The modification forms are artificial drugs, which are carried out under the premise of retaining the activity of the polypeptide. The purpose of modification includes extending half-life, increasing water solubility, reducing or eliminating toxic side effects, etc.
[0029] In some preferred embodiments of the present invention, the modified forms include but are not limited to one or more of the following aspects:
[0030] (1) Cyclic peptide synthesis: head-to-tail cyclization, side chain cyclization (lactone, lactam, ether bond, etc.), multiple disulfide bonds, monosulfide cyclization, etc.;
[0031] (2) Isotope labeling: 13 C, 15 N, 18 O and other isotope labeling;
[0032] (3) Polyethylene glycol (PEG) modification: PEG2, PEG4, PEG8, PEG12, PEG24, PEG36, PEG2000, PEG5000, PEG3400, PEG20K, PEG40K, etc.;
[0033] (4) Phosphorylation modification: phosphorylation modification of L- or D-configuration amino acids (such as threonine T, serine S), phosphorylation modification of single or multiple amino acids;
[0034] (5) Coupling protein or other carrier:
[0035] a. Peptide-protein coupling: KLH coupling, albumin coupling (such as bovine serum albumin BSA, chicken ovalbumin OVA, mouse serum albumin MSA, human serum albumin HSA), albumin affinity peptide coupling, tumor homing peptide coupling, membrane-penetrating peptide coupling, antibody Fc fragment coupling, elastin-like coupling, etc.
[0036] b. Peptide-nanocarrier coupling;
[0037] (6) Modification of N-terminal or side chain amino acids: acetylation, formylation, biotin labeling, trifluoroacetylation, benzoylation, 2-aminobenzoylation, maleimidation, chloroacetylation, bromoacetylation, succinylation, palmitation, malication, fatty acidation, formalization, chelation reaction (such as Hynic, DTPA, DOTA, NOTA modification), chloro, fluoro, bromo, nitro or methoxy substitution, fluorescent labeling (such as Cy series, Texas series, Alexa series, rhodamine, Bodipy, Rox, FAM, FITC, MCA, TAMRA, Dnp), PAS modification, etc.;
[0038] (7) C-terminal modification: amidation, esterification, aldehyde formation, alcoholization, succinylation, fluorescent labeling (such as Cy series, rhodamine, AMC, AFC, PNA, CMK, FMK), etc.
[0039] (8) Alkylation modification: N-methylation, side chain methylation, N-ethylation, N-phenylpropanylation, N-allylation, etc.;
[0040] (9) Radionuclide modification: 125I, 131I, 18F, 99mTc, 68Ga, 64Cu, 67Ga, 90Y, 111In, 177Lu, 89Zr and other radionuclide modification;
[0041] (10) Other special modifications: glycopeptides, sulfonation, MAPS, etc.
[0042] In some embodiments of the present invention, the GP2 affinity peptide is prepared by chemical synthesis. Chemical synthesis methods include solid phase synthesis (such as Fmoc method), liquid phase synthesis, solid-liquid phase synthesis. Synthesis strategies include C-terminal synthesis, N-terminal synthesis, and segmented synthesis. If conventional modification is performed at the C-terminal or N-terminal during synthesis, the polypeptide contains a modified group.
[0043] In some preferred embodiments of the present invention, the polypeptide is D GPBP-2(1-8), whose amino acid sequence is D Val- D His- D Thr- D Ser- D Arg- D His- D Ala- D Ser, that is, vhtsrhas (the constituent amino acids are all D-configuration amino acids), has a relative molecular weight of 893.948, and the polypeptide structure is as follows:
[0044]
[0045] D GPBP-2(1-8) is a modified polypeptide. The prototype polypeptide is GPBP-2, and its amino acid sequence is Ala-Thr-Leu-His-Ser-Ala-His-Arg-Ser-Thr-His-Val. The constituent amino acids are all L-configuration amino acids. It was obtained by screening the phage display peptide library. Since the polypeptide GPBP-2 is a natural amino acid, it cannot resist enzyme degradation. The reverse sequence reversal strategy of the polypeptide can maximize the direction of the polypeptide side chain and maintain the activity of the polypeptide. Therefore, the GPBP-2 peptide chain was reversed to obtain the polypeptide. D GPBP-2, sequence is D Val- D His- D Thr- D Ser- D Arg- D His- D Ala- D Ser- D His- D Leu- D Thr- D Ala. To reduce production costs, it was further shortened D GPBP-2 polypeptide chain to obtain the final optimized peptideD GPBP-2(1-8). D GPBP-2(1-8) can bind to GP2 and resist enzymatic degradation, and thus can be used to develop oral preparations or other preparations based on affinity to GP2, providing a basis and research ideas for the development of drug preparations.
[0046] The second aspect of the present invention provides a biological material related to the polypeptide of the first aspect of the present invention, wherein the biological material is any one of b1) to b12):
[0047] b1) a nucleic acid molecule encoding the polypeptide of the first aspect of the present invention;
[0048] b2) an expression cassette containing the nucleic acid molecule described in b1);
[0049] b3) a recombinant vector containing the nucleic acid molecule described in b1);
[0050] b4) a recombinant vector containing the expression cassette described in b2);
[0051] b5) a recombinant microorganism containing the nucleic acid molecule described in b1);
[0052] b6) a recombinant microorganism containing the expression cassette described in b2);
[0053] b7) a recombinant microorganism containing the recombinant vector described in b3);
[0054] b8) a recombinant microorganism containing the recombinant vector described in b4);
[0055] b9) transgenic animal cell lines containing the nucleic acid molecule described in b1);
[0056] b10) a transgenic animal cell line containing the expression cassette described in b2);
[0057] b11) a transgenic animal cell line containing the recombinant vector described in b3);
[0058] b12) A transgenic animal cell line containing the recombinant vector described in a4).
[0059] In some embodiments of the invention, the transgenic animal cell line does not contain reproductive material.
[0060] The third aspect of the present invention provides use of the polypeptide of the first aspect of the present invention or the biomaterial of the second aspect of the present invention in at least one of (1) to (5):
[0061] (1) Affinity GP2 protein, wherein the GP2 may be a wild-type protein of human or mouse origin or a mutant protein that still retains its activity;
[0062] (2) preparing products for targeting GP2 in vivo and in vitro;
[0063] (3) Preparation of products for treating or preventing tumors;
[0064] (4) qualitatively and / or quantitatively detecting whether GP2 protein is expressed, its expression location or its expression level;
[0065] (5) Prepare products for qualitatively and / or quantitatively detecting whether GP2 protein is expressed, its expression location or its expression level.
[0066] In some embodiments of the present invention, the tumor includes at least one of breast cancer, adenocarcinoma, gastric cancer, colorectal cancer, ovarian cancer, esophageal cancer, lung cancer, and melanoma; or a tumor with high expression of GP2.
[0067] The fourth aspect of the present invention provides a vaccine comprising the polypeptide of the first aspect of the present invention or the biological material of the second aspect of the present invention.
[0068] In some embodiments of the present invention, the immunization of the vaccine comprises nasal, oral, subcutaneous, intramuscular, intravenous, intraperitoneal or intradermal injection.
[0069] In some embodiments of the present invention, the vaccine further comprises an adjuvant and / or a pharmaceutically acceptable carrier.
[0070] In some embodiments of the present invention, examples of pharmaceutically acceptable carrier components include binders (syrup, gum arabic, gelatin, sorbitol, tragacanth, polyvinyl pyrrolidone, etc.), fillers (lactose, sucrose, starch, calcium phosphate, sorbitol, glycine, etc.), lubricants (magnesium stearate, talc, polyethylene glycol, etc.), disintegrants (starch, microcrystalline cellulose, etc.), wetting agents (sodium lauryl sulfate, etc.), suspending agents (sorbitol, syrup, methylcellulose, glucose syrup, gelatin, hydrogenated edible fats, etc.), emulsifiers (lecithin, etc.), Fat, sorbitan monooleate, gum arabic, etc.), non-aqueous carriers (almond oil, fractionated coconut oil or glycerol, propylene glycol, ethanol and other hydrophobic esters, etc.), preservatives (methyl paraben or propyl paraben, sorbic acid, etc.), fragrances (synthetic flavors, natural flavors, etc.), sweeteners (sucrose, stevia, xylitol, etc.), pH adjusters (sodium bicarbonate, potassium carbonate, etc.), powders (pigments, dyes, resins, etc.), thickeners (gum arabic, methyl cellulose, etc.), antioxidants (vitamin C, vitamin E, etc.), etc.
[0071] The fifth aspect of the present invention provides a biological material comprising the polypeptide of the first aspect of the present invention or the second aspect of the present invention.
[0072] In some embodiments of the present invention, the product includes at least one of a drug, a reagent, a kit, a probe, and an antigen-coupled species.
[0073] The beneficial effects of the present invention are:
[0074] GP2 is an endocytic receptor specifically expressed in intestinal M cells. The present invention obtains GP2 affinity peptides (such as GPBP-2) by solid phase screening of phage display peptide library, and optimizes it to obtain the first GP2 affinity D peptide resistant to gastrointestinal proteolysis D GPBP-2(1-8), D GPBP-2 (1-8) has specific affinity for human and mouse GP2, and can be specifically internalized into cells that overexpress GP2 receptors. D GPBP-2(1-8) can be used as a candidate molecule and research idea for developing drugs based on affinity to GP2, and for developing preparations for anti-tumor or other diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0075] Figure 1 HPLC detection of peptide GPBP-2 and D Enzymatic degradation of GPBP-2(1-8) in simulated gastrointestinal fluid.
[0076] Figure 2 For flow cytometry detection of peptide GPBP-2 and D Internalization of GPBP-2(1-8) in cells overexpressing GP2.
[0077] Figure 3 Peptide D The effects of oral drugs based on GPBP-2(1-8) affinity for GP2 on tumors. DETAILED DESCRIPTION
[0078] The present invention is further described in detail below through specific examples.
[0079] It should be understood that these embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention.
[0080] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0081] The term "retro-inversion" refers to a peptide sequence in which one or more amino acids are D amino acids (inversion), and the peptide sequence is in reverse order (inversion). In some embodiments, there may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 D amino acids. In some embodiments, the retro-inversion peptide includes amino acids with alternating chirality. In certain embodiments, the retro-inversion peptide includes all D amino acids. As used herein, chirality refers to the D and L isomers of amino acids. For illustration, the retro-inversion peptide with the sequence CX1X2X3C will be reversed to have the sequence CX3X2X1C, wherein at least one or more amino acids are D amino acids. Peptides made of D-amino acids are metabolically stable because they are poor substrates for proteases, which have evolved to degrade proteins and peptides made of L-amino acids. However, D-peptides have reverse handedness in, for example, a helical structure, i.e., the amino acid side chains are positioned as mirror images. Reversing the sequence order in the D-peptide provides a structure that mimics the L-peptide analog in terms of side chain orientation, in other words, retro-inverso isomerization. Short non-helical retro-inverso peptides can functionally mimic their native L-protein counterparts in target binding.
[0082] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0083] Example 1 Phage display peptide library solid phase screening GP2 affinity peptide, polypeptide synthesis and purification
[0084] Phage display peptide library solid phase screening GP2 affinity peptide: dilute the eukaryotic GP2 protein (PROSPEC, CAT#: PRO-115) with coating solution, take 100μL and place it in a well of a 96-well plate, and coat it at 4℃ overnight. The next morning, remove the sealing film, carefully aspirate the coating solution in the well plate with a pipette, and slowly add the blocking solution, and then place it at 4℃ for more than three hours. Wash the blocked wells with 0.1% TBST for a total of 4 times. Be careful to add the washing solution each time you wash, and ensure that the well plate cannot dry to avoid the loss and inactivation of the coated GP2 protein. Take out the peptide library from the -20℃ refrigerator, dilute it 10 times, and incubate it with the target protein for 60min. This is the first round of affinity between phage and target protein GP2. The incubation time for the second, third, and fourth rounds is 40min, 30min, and 20min respectively. The unbound phages were washed with 0.1% TBST, and then the phages bound to the GP2 protein were eluted with Gly-HCl at pH 2.2. This screening was performed for four rounds, and the phages eluted in the fourth round were sent for sequencing to obtain the polypeptide sequence.
[0085] Peptide synthesis and purification: Swell the Fmoc resin and deprotect it. The resin turns brown or dark blue, indicating that the deprotection is complete and subsequent operations can be performed. Weigh the amino acid corresponding to the peptide chain (generally 2 to 4 times the molar number of the resin), dissolve it in 2 mL of DMF and add it to the synthesizer, then add the corresponding amount of HOBT and DIC, and react for more than 3 hours. After adding the last amino acid to the resin, remove the amino acid protecting group and cut the peptide from the resin using trifluoroacetic acid. Finally, use preparative chromatography to purify the peptide.
[0086] The GP2 affinity peptides obtained by screening are shown in Table 1. The peptides in the table are all composed of L-configuration amino acids.
[0087] Table 1 Affinity of peptides obtained by phage screening and human GP2 protein detected by microcalorimetry
[0088]
[0089]
[0090] Example 2
[0091] This example uses microthermophoresis to detect the affinity of the polypeptide screened in Example 1 with GP2. The specific process is as follows:
[0092] The GP2 protein was dissolved in PBST solution to 800nM, diluted down to 16 concentrations with a 2-fold concentration gradient, and placed on ice for use. The RED-tris-NTA His-Tag dye was diluted to 50nM with PBST, and the dye and protein were mixed at a volume ratio of 1:1, and incubated at room temperature in the dark for 30min. The incubation process is the labeling process. The peptide was dissolved in PBST solution to 100μM, diluted down to 16 concentrations with a 2-fold concentration gradient, and mixed with the dye (50nM concentration) at a volume ratio of 1:1, and incubated at room temperature in the dark for 5min to allow the peptide to better bind to the target protein. The mixed samples were carefully aspirated using a capillary and placed in the MST tray in order for detection.
[0093] The test results are shown in Table 1 , among which GPBP-2 (peptide sequence is ATLHSAHRSTHV) has a high frequency of occurrence and a high affinity with human GP2 protein, and this peptide was used for subsequent experiments.
[0094] Example 3
[0095] The amino acid sequence of GPBP-2 is Ala-Thr-Leu-His-Ser-Ala-His-Arg-Ser-Thr-His-Val (ATLHSAHRSTHV), and the constituent amino acids are all L-configuration amino acids. Therefore, in this example, GPBP-2 is treated to change some amino acids at both ends of GPBP-2 from L-type to D-configuration (the synthesis and purification of the polypeptide are the same as in Example 1), and the affinity of the D-configuration amino acid protection polypeptide at both ends of the GPBP-2 polypeptide and the human GP2 protein is detected by microcalorimetry (the experimental process is the same as in Example 2).
[0096] The results are shown in Table 2. a-v GPBP-2 a-thv and GPBP-2 at-thv Except for 1, the other peptides can bind to GP2 protein.
[0097] Table 2 Microcalorimetry detection of the affinity of the D-amino acid protected peptides at both ends of GPBP-2 peptide to human GP2 protein
[0098]
[0099]
[0100] Note: In the sequences in Table 2, lowercase letters indicate that the amino acids are in the D configuration, and uppercase letters indicate that the amino acids are in the L configuration.
[0101] Example 4
[0102] Since the polypeptide GPBP-2 is a natural amino acid, it cannot resist enzymatic degradation. The reverse order reversal strategy of the polypeptide can maximize the direction of the polypeptide side chain and maintain the activity of the polypeptide. Therefore, this example adopts the reverse order reversal strategy of the polypeptide to reverse the peptide chain of the polypeptide GPBP-2 to obtain the polypeptide D GPBP-2, amino acid sequence is D Val- D His- D Thr- D Ser- D Arg- D His- D Ala- D Ser- D His- D Leu- D Thr- D Ala (i.e., vhtsrhashlta, SEQ ID NO: 16). In order to reduce production costs, further D The GPBP-2 polypeptide chain was truncated (Table 3), and the reverse sequence of the polypeptide GPBP-2 was detected by microcalorimetry.D The affinity of GPBP-2 for human GP2, and D The affinity of the truncated peptide of GPBP-2 to human GP2. The synthesis and purification of the polypeptide were the same as in Example 1, and the microcalorimetric swell detection process was the same as in Example 2.
[0103] The results are shown in Table 3, where the peptide D The affinity of GPBP-2(1-8) to human GP2 is higher than that of the reverse sequence of GPBP-2 D GPBP-2 and others D The truncated peptide of GPBP-2 is good, and the peptide is selected for subsequent experiments D GPBP-2(1-8) was performed.
[0104] Table 3 Microcalorimetry detection of reversed peptides of GPBP-2 D The affinity of GPBP-2 for human GP2, and D Affinity of GPBP-2 truncated peptides for human GP2
[0105]
[0106]
[0107] Example 5 HPLC detection of peptide enzyme degradation stability
[0108] To investigate the peptide D Whether GPBP-2 (1-8) is resistant to gastrointestinal proteolysis, this example provides a polypeptide gastrointestinal enzyme degradation stability test, which is carried out in simulated gastric fluid SGF (pH 1.2, containing pepsin) and simulated intestinal fluid SIF (pH 6.8, containing trypsin). Each polypeptide ( D GPBP-2(1-8) and D GPBP-2) was weighed in two portions, one portion was dissolved in SGF and the other portion was dissolved in SIF, and placed in a 37°C constant temperature incubator. 200 μL of the reaction product was taken out at different time points and placed in a 1.5 mL EP tube for gastrointestinal enzymatic degradation at each time point; 100 μL of 10% perchloric acid solution was added to the samples taken out at the above different time points, and the mixture was quickly vortexed and mixed evenly; the supernatant was collected after centrifugation (10000 rpm, 10 min, 4°C), and the gastrointestinal enzymatic degradation at each time point was monitored by RP-HPLC after filtering with a 0.22 μm filter.
[0109] The results are as follows Figure 1 As shown, D GPBP-2(1-8) has good resistance to gastrointestinal proteolysis.
[0110] Example 6 Flow cytometry to detect the endocytosis of polypeptides
[0111] This example uses flow cytometry to detect D The specific process of GPBP-2(1-8) being internalized by cells is as follows:
[0112] Lentivirus transfection was used to construct cell lines overexpressing human and mouse GP2 (denoted as 293T-pLVX, 293T-hGP2 and 293T-mGP2) to detect the affinity of the peptides for human and mouse GP2. The peptides with biotin tags were weighed on an electronic balance, and the concentration of each peptide was adjusted to 20 μM with PBS. 50 μL of each peptide was added to the above three cells, vortexed and placed on ice for 30 min. During the co-incubation of cells and peptides, the fluorescent label solution SA-PE was prepared so that each 50 μL PBS contained 0.3 μL SA-PE stock solution. 1 mL PBS was added to the cells, centrifuged (3000 rpm, 5 min, 4 ° C), and the supernatant was discarded. This operation was repeated 3 times. After fully washing away the unbound peptides, the cells were gently suspended using the small amount of liquid remaining in the tube, 200 μL of fixative was added, and fixed at room temperature for 30 min. After adding 800 μL of membrane permeabilization agent to the cells, centrifuge directly (3000 rpm, 5 min, 4°C) and discard the supernatant, add 50 μL of the above-prepared SA-PE solution, vortex mix and place on ice for 30 min. Add 1 mL of PBS to the cells, centrifuge (3000 rpm, 5 min, 4°C) and discard the supernatant, add 200 μL of PBS to resuspend the cells, and monitor the cell fluorescence intensity by flow cytometry.
[0113] The results are as follows Figure 2 As shown, D GPBP-2(1-8) has specific affinity for human and mouse GP2, and can be specifically internalized into cells overexpressing GP2 receptors.
[0114] Example 7 Antitumor Experiment of Preparation Based on GP2 Affinity Peptide
[0115] This example explores the B16-OVA model in C57BL / 6 mice D The anti-tumor effects of oral vaccines before and after GPBP-2(1-8) modification are as follows:
[0116] Collect B16-OVA melanoma cells with good growth status and adjust the cell concentration to 1×10 6 Each BABL / c mouse (5 weeks old, weighing about 15 g, purchased from Zhuhai Bestone Laboratory Animal Co., Ltd.) was subcutaneously injected with 200 μL (2×10 5cells) to construct the B16-OVA model of C57BL / 6 mice; from the 8th day of tumor bearing, the volume of the mice grew to about 40-80 mm 3 The S-shaped groups were divided into saline control group, OVA protein group (100 μg per mouse), D The GPBP-2 (1-8) polypeptide-modified drug group (3 mg of polypeptide-modified carrier containing 100 μg of OVA protein) was orally administered. The mice were weighed every other day using an electronic balance and the mouse tumors were measured using a digital vernier caliper. The changes in mouse tumor volume were calculated and recorded according to the formula V = 1 / 2 × a (length) × b (width) × c (height).
[0117] The results are as follows Figure 3 As shown, oral peptide D GPBP-2(1-8) modified formulations can inhibit tumor growth.
[0118] The embodiments of the present invention are described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.
Claims
1. A polypeptide, It is characterized in that The polypeptide is any one of a1) to a4): a1) the amino acid sequence is shown in any one of SEQ ID NO: 1 to SEQ ID NO: 11 and SEQ ID NO: 13; a2) a retro-inverted form of the amino acid sequence of X1-X2-X3-X4-X5-X6-HRSTHV, Among them, X1 does not exist or is A; X2 does not exist or is T; X3 does not exist or is L; X4 does not exist or is H; X5 does not exist or is S; X6 does not exist or is A; a3) a retro-inverted form of the amino acid sequence of ATLHSA-X7-X8-X9-X10-X11, Wherein, X7 does not exist or is H; X8 does not exist or is R; X9 does not exist or is S; X10 does not exist or is T; X11 does not exist or is H; a4) A modified form of any of the polypeptides a1) to a3).
2. The polypeptide according to claim 1, It is characterized in that All amino acids in a1) are L-amino acids, or at least the amino acids at both ends of the polypeptide are D-amino acids.
3. The polypeptide according to claim 1, It is characterized in that a2) The amino acids of the polypeptide are shown in any one of SEQ ID NO: 16 to SEQ ID NO: 22; all the amino acids of the peptide are D-amino acids.
4. The polypeptide according to claim 1, It is characterized in that a3) The amino acids of the polypeptide are shown in any one of SEQ ID NO: 24 to SEQ ID NO: 28; all the amino acids of the peptide are D-amino acids.
5. The polypeptide according to any one of claims 1 to 4, It is characterized in that The modification sites of the modification forms described in a4) include N-terminal modification, C-terminal modification, backbone modification, side chain modification and / or amino acid modification.
6. A biological material related to the polypeptide according to any one of claims 1 to 5, wherein the biological material is any one of b1) to b12): b1) a nucleic acid molecule encoding the polypeptide according to any one of claims 1 to 5; b2) an expression cassette containing the nucleic acid molecule described in b1); b3) a recombinant vector containing the nucleic acid molecule described in b1); b4) a recombinant vector containing the expression cassette described in b2); b5) a recombinant microorganism containing the nucleic acid molecule described in b1); b6) a recombinant microorganism containing the expression cassette described in b2); b7) a recombinant microorganism containing the recombinant vector described in b3); b8) a recombinant microorganism containing the recombinant vector described in b4); b9) transgenic animal cell lines containing the nucleic acid molecule described in b1); b10) a transgenic animal cell line containing the expression cassette described in b2); b11) a transgenic animal cell line containing the recombinant vector described in b3); b12) A transgenic animal cell line containing the recombinant vector described in a4).
7. Use of the polypeptide according to any one of claims 1 to 5 or the biomaterial according to claim 6 in at least one of (1) to (5): (1) Affinity GP2 protein, wherein the GP2 may be a wild-type protein of human or mouse origin or a mutant protein that still retains its activity; (2) preparing products for targeting GP2 in vivo and in vitro; (3) Preparation of products for treating or preventing tumors; (4) qualitatively and / or quantitatively detecting whether GP2 protein is expressed, its expression location or its expression level; (5) Prepare products for qualitatively and / or quantitatively detecting whether GP2 protein is expressed, its expression location or its expression level.
8. A vaccine comprising the polypeptide according to any one of claims 1 to 5 or the biological material according to claim 6.
9. The vaccine according to claim 8, It is characterized in that Immunization with the vaccine includes nasal, oral, and subcutaneous, intramuscular, intravenous, intraperitoneal or intradermal injection.
10. A product comprising the polypeptide according to any one of claims 1 to 5 or the biomaterial according to claim 6; preferably, the product comprises at least one of a drug, a reagent, a kit, a probe, and an antigen-coupled species.
